The Monoclonal Antibody Therapy Market is segmented according to application, antibody type, production method, distribution channel, and region. These segments reflect the diverse therapeutic uses and manufacturing approaches associated with monoclonal antibody products.

By application, the market includes oncology, autoimmune diseases, infectious diseases, and cardiovascular diseases. Oncology represents the dominant application, accounting for 52.9% of the market share according to Market Research Future. The strong position of oncology is supported by the increasing development and adoption of antibody-based cancer treatments.

By type, monoclonal antibodies are categorized into IgG, IgM, IgA, and IgE. IgG represents the largest segment, with a 63.4% share, supported by its broad therapeutic applications and extended half-life.

Production methods include hybridoma technology, recombinant DNA technology, and transgenic animals. Hybridoma technology remains a major production method, while recombinant DNA technology is gaining attention because of advances in genetic engineering and the ability to support the development of specialized antibodies.

Hospital pharmacies represent the largest distribution channel because many monoclonal antibody therapies require specialized administration and healthcare monitoring. Retail and online pharmacies also contribute to distribution as access to biologic medicines expands.

Regionally, North America leads the global market, followed by Europe and Asia-Pacific. Increasing healthcare investment in emerging economies is expected to create further opportunities for manufacturers and pharmaceutical companies.